论文部分内容阅读
目的评价恩度联合GP化疗方案与单用GP化疗治疗晚期非小细胞肺癌疗效及安全性。方法根据纳入标准和排除标准,在CNKI及万方等数据库进行检索,收集了2002～2012年有关恩度联合GP化疗方案治疗非小细胞肺癌的临床随机对照文献,其中符合标准的中文文献共6篇,样本量275例,用RevMan5.1软件对相关数据进行Meta分析。结果恩度联合GP化疗治疗非小细胞肺癌的OR总有效率=2.17(95%CI1.31～3.60),P=0.003;OR疾病控制率=2.52(95%CI1.34～4.74),P=0.004。不良反应的数据分析无统计学意义。结论本研究在一定程度上反映了恩度联合GP方案在治疗晚期非小细胞肺癌疗效和安全性优于单用GP化疗方案。
Objective To evaluate the efficacy and safety of Endo combined with GP chemotherapy and GP chemotherapy alone in the treatment of advanced non-small cell lung cancer. Methods According to the inclusion criteria and exclusion criteria, CNKI and Wanfang searched databases and collected clinical randomized controlled articles on non-small cell lung cancer (NSCLC) from 2002 to 2012. The Chinese documents that met the criteria were 6 There were 275 sample cases and a meta-analysis of the relevant data using RevMan 5.1 software. Results The total effective rate of Endo combined with GP chemotherapy in the treatment of non-small cell lung cancer was 2.17(95%CI1.31~3.60), P=0.003; OR control rate of disease=2.52(95%CI1.34~4.74), P= 0.004. The data analysis of adverse reactions was not statistically significant. Conclusion This study to a certain extent reflects the efficacy and safety of Endo combined with GP regimen in the treatment of advanced non-small cell lung cancer is superior to that of GP chemotherapy alone.